Trimel Completes Private Placement of Common Shares

Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that it has
completed the previously announced sale of an aggregate 28,801,000 common shares
of the Company at a purchase price of CDN$0.62 per common share for gross
proceeds of CDN$17,856,620. The sale of the common shares was completed pursuant
to an underwriting agreement with Cormark Securities Inc. ("Cormark") and
subscription agreements with individual purchasers. In connection with the
private placement, the Company paid a commission to Cormark equal to
approximately 5.5% of the gross proceeds from the placement. All common shares
issued as part of the private placement are subject to a four month hold period
in accordance with applicable securities laws.


The Company intends to use the full net proceeds from the private placement to
repay a significant portion of a convertible promissory note previously issued
to First Generation Capital Inc. ("First Generation"), a company affiliated with
Mr. Ian Ihnatowycz, the Chairman of the Board of Directors of the Company.
Following this repayment, First Generation has advised that it intends to
convert a portion of the note into a total of 8,945,796 common shares following
August 21, 2014. Following such conversion, First Generation would hold
approximately 23.7% of the Company's common shares, thereby maintaining its
current securityholding percentage. The indebtedness remaining under the note
(expected to equal approximately US$4.1 million) following such conversion and
repayment would remain outstanding in accordance with the terms of the note and
no longer be convertible into common shares after such time.


About Trimel 

Trimel is a specialty pharmaceutical company involved in the sale, distribution,
and development of products with a focus in men's health, women's health, and
respiratory medicine. Natesto(TM), a product utilizing Trimel's licensed nasal
gel technology, has been approved for sale in the United States by the FDA. For
more information, please visit www.trimelpharmaceuticals.com.


Notice regarding forward-looking statements: 

Information in this press release that is not current or historical factual
information may constitute forward looking information within the meaning of
securities laws. Implicit in this information are assumptions regarding our
future operational results. These assumptions, although considered reasonable by
the company at the time of preparation, may prove to be incorrect. Readers are
cautioned that actual performance of the company is subject to a number of risks
and uncertainties and could differ materially from what is currently expected as
set out above. For more exhaustive information on these risks and uncertainties
you should refer to our annual information form dated March 5, 2014 which is
available at www.sedar.com. Forward-looking information contained in this press
release is based on our current estimates, expectations and projections, which
we believe are reasonable as of the current date. You should not place undue
importance on forward-looking information and should not rely upon this
information as of any other date. While we may elect to, we are under no
obligation and do not undertake to update this information at any particular
time, whether as a result of new information, future events or otherwise, except
as required by applicable securities law.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536
[e-mail]
www.trimelpharmaceuticals.com